These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15621786)

  • 1. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.
    Smolewski P; Szmigielska-Kaplon A; Cebula B; Jamroziak K; Rogalinska M; Kilianska Z; Robak T
    Leuk Lymphoma; 2005 Jan; 46(1):87-100. PubMed ID: 15621786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
    Bogusz J; Majchrzak A; Mędra A; Cebula-Obrzut B; Robak T; Smolewski P
    Postepy Hig Med Dosw (Online); 2013 Mar; 67():107-18. PubMed ID: 23475487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Robak P; Linke A; Cebula B; Robak T; Smolewski P
    Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
    Nückel H; Frey UH; Röth A; Dührsen U; Siffert W
    Eur J Pharmacol; 2005 May; 514(2-3):217-24. PubMed ID: 15910809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.
    Stanglmaier M; Reis S; Hallek M
    Ann Hematol; 2004 Oct; 83(10):634-45. PubMed ID: 15309525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
    Smolewski P; Duechler M; Linke A; Cebula B; Grzybowska-Izydorczyk O; Shehata M; Robak T
    Leuk Res; 2006 Dec; 30(12):1521-9. PubMed ID: 16630656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Grdisa M
    Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging treatments for chronic lymphocytic leukaemia.
    Robak T; Jamroziak K; Robak P
    Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
    Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG
    Leuk Lymphoma; 2007 Oct; 48(10):1931-9. PubMed ID: 17917961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
    Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE
    Leuk Res; 2008 Dec; 32(12):1849-56. PubMed ID: 18584865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
    Zent CS; Chen JB; Kurten RC; Kaushal GP; Lacy HM; Schichman SA
    Leuk Res; 2004 May; 28(5):495-507. PubMed ID: 15068903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.